Role of host interleukin 1β gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in Helicobacter pylori-positive Turkish patients with dyspepsia

Journal of Gastroenterology

Volumn 43, Issue 9, 2008, Pages 705-710

  Erzin, Yusuf ^a   Koksal, Vedat ^b   Altun, Sibel ^a   Dobrucali, Ahmet ^a   Aslan, Mustafa ^a   Erdamar, Sibel ^a   Goksel, Süha ^a   Dirican, Ahmet ^a   Kocazeybek, Bekir ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b BURC Molecular Diagnostic Laboratory Turkey   (Turkey)

Author keywords

Helicobacter pylori; Interleukin 1B gene; Interleukin receptor antagonist gene

Indexed keywords

BACTERIAL PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; PROTEIN BABA2; PROTEIN CAGE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DUODENUM ULCER; DYSPEPSIA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER PYLORI; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; STOMACH CANCER; TURKEY (REPUBLIC); VARIABLE NUMBER OF TANDEM REPEAT;

ADHESINS, BACTERIAL; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DUODENAL ULCER; DYSPEPSIA; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS;

EID: 52749093626     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2220-7     Document Type: Article

References (38)

1. Blaser MJ. Ecology of Helicobacter pylori in the human stomach. J Clin Invest 1997;100:759-762.
2. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740.
3. Blaser MJ. Linking Helicobacter pylori to gastric cancer. Nat Med 2000;6:376-377.
4. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
5. Mobley HL. Defining Helicobacter pylori as a pathogen: Strain heterogeneity and virulence. Am J Med 1996;100:2S-9S.
6. Atherton JC. The clinical relevance of strain types of Helicobacter pylori. Gut 1997;40:701-703.
7. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
8. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, et al. Interleukin-1b and interleukin-1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001;121:823-829.
9. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425-429.
10. Basso D, Scrigner M, Toma A, Navaglia F, Di Mario F, Rugge M, et al. Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res 1996;26:207-210.
11. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 1998;16:27-55.
12. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998;47:195-198.
13. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-310.
14. El-Omar EM. The importance of interleukin-1beta in Helicobacter pylori associated disease. Gut 2001;48:743-747.
15. Koivurova OP, Karhukorpi JM, Joensuu ET, Koistinen PO, Valtonen JM, Karttunen TJ, et al. IL-1 RN 2/2 genotype and simultaneous carriage of genotypes IL-1 RN 2/2 and IL-1beta-511 T/T associated with oesophagitis in Helicobacter pylori-negative patients. Scand J Gastroenterol 2003;38:1217-1222.
16. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Pub 2004;157:327-349.
17. Furuta T, Shirai N, Sugimoto M. Controversy in polymorphisms of interleukin-1beta in gastric cancer risks. J Gastroenterol 2004;39:501-503.
18. Erzin Y, Koksal V, Altun S, Dobrucali A, Aslan M, Erdamar S, et al. Prevalence of Helicobacter pylori vacA, cagA, cagE, iceA, babA2 genotypes and correlation with clinical outcome in Turkish patients with dyspepsia. Helicobacter 2006;11:574-580.
19. Shields PG, Haris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000;18:2309-2315.
20. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747-751.
21. Gonzales CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2004;100:249-260.
22. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, et al. Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002;94:1680-1687.
23. Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, et al. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphism in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Ann Oncol 2005;16:887-892.
24. Karaoguz H, Icli F. Cancer Problem in Turkiye. J Ankara Med School 1993;15:547-558.
25. World Health Organization. World cancer report. Geneva, Switzerland: International Agency for Research on Cancer; 2003.
26. Kato S, Onda M, Yamada S, Matsuda N, Tokunaga A, Matsukura N. Association of the interleukin-1β genetic polymorphism and gastric cancer risk in Japanese. J Gastroenterol 2001;36:696-699.
27. Lee SG, Kin B, Choi WY, Lee IC, Choi JW, Song KY. Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B-31C/+ and IL-1RN*2/*2) and gastric cancer/duodenal ulcer in Korean population. Cytokine 2003;21:167-171.
28. Hamajima N, Matsuo K, Saito T, Tajima K, Okuma K, Yamao K, et al. Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection. Jpn J Cancer Res 2001;92:383-389.
29. Lee S, Hong S, Yoon Y, Yang I, Song K. Characterization of publicly available SNPs in the Korean population. Hum Mutat 2001;17:281-284.
30. Ertem D, Harmanci H, Pehlivanoglu E. Helicobacter pylori infection in Turkish preschool and school children: Role of socioeconomic factors and breast feeding. Turk J Pediatr 2003;45:114-122.
31. Us D, Hascelik G. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect 1998;37:148-150.
32. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186.
33. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
34. Bretagne JF.Could Helicobacter pylori treatment reduce stomach cancer risk? Gastroenterol Clin Biol 2003;27:440-452.
35. Hunt RH, Fallone C, Veldhuyzen VZ, Sherman P, Smaill F, Thomson AB. Risks and benefits of Helicobacter pylori eradication: Current status. Can J Gastroenterol 2002;16:57-62.
36. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of populationbased Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999;159:142-148.
37. Parsonnet J, Haris RA, Hack HM, Owens DK. Modeling costeffectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996;348:150-154.
38. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.